Ulcerative Colitis - Pipeline Review, H1 2018

  • ID: 4518523
  • Drug Pipelines
  • 482 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Atlantic Bio Sci LLC
  • Eli Lilly and Co
  • Istesso Ltd
  • Oncobiologics Inc
  • Sareum Holdings Plc
  • MORE
Ulcerative Colitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2018, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon.

The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights:

This latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 14, 37, 30, 1, 49, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Atlantic Bio Sci LLC
  • Eli Lilly and Co
  • Istesso Ltd
  • Oncobiologics Inc
  • Sareum Holdings Plc
  • MORE
Introduction

Ulcerative Colitis - Overview

Ulcerative Colitis - Therapeutics Development

Ulcerative Colitis - Therapeutics Assessment

Ulcerative Colitis - Companies Involved in Therapeutics Development

Ulcerative Colitis - Drug Profiles

Ulcerative Colitis - Dormant Projects

Ulcerative Colitis - Discontinued Products

Ulcerative Colitis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Ulcerative Colitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Ulcerative Colitis - Pipeline by 4D Pharma PLC, H1 2018

Ulcerative Colitis - Pipeline by AbbVie Inc, H1 2018

Ulcerative Colitis - Pipeline by AbGenomics International Inc, H1 2018

Ulcerative Colitis - Pipeline by Abivax SA, H1 2018

Ulcerative Colitis - Pipeline by Adello Biologics LLC, H1 2018

Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H1 2018

Ulcerative Colitis - Pipeline by Allergan Plc, H1 2018

Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H1 2018

Ulcerative Colitis - Pipeline by Am-Pharma BV, H1 2018

Ulcerative Colitis - Pipeline by Amgen Inc, H1 2018

Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H1 2018

Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H1 2018

Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, H1 2018

Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H1 2018

Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H1 2018

Ulcerative Colitis - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H1 2018

Ulcerative Colitis - Pipeline by Celgene Corp, H1 2018

Ulcerative Colitis - Pipeline by Celltrion Inc, H1 2018

Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H1 2018

Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2018

Ulcerative Colitis - Pipeline by Coherus BioSciences Inc, H1 2018

Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2018

Ulcerative Colitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2018

Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H1 2018

Ulcerative Colitis - Pipeline by Eli Lilly and Co, H1 2018

Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2018

Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H1 2018

Ulcerative Colitis - Pipeline by Ferring International Center SA, H1 2018

Ulcerative Colitis - Pipeline by Fresenius SE & Co KGaA, H1 2018

Ulcerative Colitis - Pipeline by Galapagos NV, H1 2018

Ulcerative Colitis - Pipeline by Genentech Inc, H1 2018

Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, H1 2018

Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H1 2018

Ulcerative Colitis - Pipeline by IB Pharmaceuticals Inc, H1 2018

Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2018

Ulcerative Colitis - Pipeline by Inception Sciences Inc, H1 2018

Ulcerative Colitis - Pipeline by InDex Pharmaceuticals Holding AB, H1 2018

Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Ulcerative Colitis - Pipeline by Istesso Ltd, H1 2018

Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2018

Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018

Ulcerative Colitis - Pipeline by Keystone Biologics Inc, H1 2018

Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Ulcerative Colitis - Pipeline by LG Chem Ltd, H1 2018

Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2018

Ulcerative Colitis - Pipeline by Lycera Corp, H1 2018

Ulcerative Colitis - Pipeline by Merck & Co Inc, H1 2018

Ulcerative Colitis - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2018

Ulcerative Colitis - Pipeline by Morphotek Inc, H1 2018

Ulcerative Colitis - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2018

Ulcerative Colitis - Pipeline by Noxopharm Ltd, H1 2018

Ulcerative Colitis - Pipeline by Ogeda SA, H1 2018

Ulcerative Colitis - Pipeline by Oncobiologics Inc, H1 2018

Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, H1 2018

Ulcerative Colitis - Pipeline by Palatin Technologies Inc, H1 2018

Ulcerative Colitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Ulcerative Colitis - Pipeline by Pfizer Inc, H1 2018

Ulcerative Colitis - Pipeline by Principia Biopharma Inc, H1 2018

Ulcerative Colitis - Pipeline by Protab Ltd, H1 2018

Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2018

Ulcerative Colitis - Pipeline by Protalix BioTherapeutics Inc, H1 2018

Ulcerative Colitis - Pipeline by Qu Biologics Inc, H1 2018

Ulcerative Colitis - Pipeline by Re-Pharm Ltd, H1 2018

Ulcerative Colitis - Pipeline by Rebiotix Inc, H1 2018

List of Figures

Number of Products under Development for Ulcerative Colitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4D Pharma PLC
  • AbbVie Inc
  • AbGenomics International Inc
  • Abivax SA
  • Adello Biologics LLC
  • Akebia Therapeutics Inc
  • Allergan Plc
  • Alpha Cancer Technologies Inc
  • Am-Pharma BV
  • Amgen Inc
  • Aptevo Therapeutics Inc
  • Arena Pharmaceuticals Inc
  • Artelo Biosciences Inc
  • Atlantic Bio Sci LLC
  • Atlantic Healthcare Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celltrion Inc
  • ChemoCentryx Inc
  • ChironWells GmbH
  • Coherus BioSciences Inc
  • Cosmo Pharmaceuticals NV
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • EA Pharma Co Ltd
  • Eli Lilly and Co
  • Enceladus Pharmaceuticals BV
  • Enterome Bioscience SA
  • Ferring International Center SA
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genentech Inc
  • Genor BioPharma Co Ltd
  • GlaxoSmithKline Plc
  • IB Pharmaceuticals Inc
  • iCo Therapeutics Inc.
  • Inception Sciences Inc
  • InDex Pharmaceuticals Holding AB
  • Intas Pharmaceuticals Ltd
  • Istesso Ltd
  • Johnson & Johnson
  • Kaken Pharmaceutical Co Ltd
  • Keystone Biologics Inc
  • Kyowa Hakko Kirin Co Ltd
  • LG Chem Ltd
  • LIPID THERAPEUTICS GmbH
  • Lycera Corp
  • Merck & Co Inc
  • Miyarisan Pharmaceutical Company Ltd
  • Morphotek Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Noxopharm Ltd
  • Ogeda SA
  • Oncobiologics Inc
  • OSE Immunotherapeutics
  • Palatin Technologies Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Principia Biopharma Inc
  • Protab Ltd
  • Protagonist Therapeutics Inc
  • Protalix BioTherapeutics Inc
  • Qu Biologics Inc
  • Re-Pharm Ltd
  • Rebiotix Inc
  • RedHill Biopharma Ltd
  • Reliance Life Sciences Pvt Ltd
  • Sandoz International GmbH
  • Sareum Holdings Plc
  • Seres Therapeutics Inc
  • Shire Plc
  • Sigmoid Pharma Ltd
  • Stelic Institute & Co Inc
  • sterna biologicals Gmbh & Co KG
  • Swedish Orphan Biovitrum AB
  • Synedgen Inc
  • Synergy Pharmaceuticals Inc
  • Synlogic Inc
  • Takeda Pharmaceutical Co Ltd
  • Theravance Biopharma Inc
  • Thetis Pharmaceuticals LLC
  • Tillotts Pharma AG
  • TopiVert Ltd
  • Torrent Pharmaceuticals Ltd
  • TTY Biopharm Company Ltd
  • UCB SA
  • Ventria Bioscience
  • Vivelix Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll